Drug intelligence / Profile preview

QX007N

Development stage: Preclinical
Lead developer: Qyuns Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

QX007N is a monoclonal antibody developed by Qyuns Therapeutics that targets interleukin-33 (IL-33). IL-33 is an alarmin cytokine released from damaged epithelial cells that plays a key role in driving both type 2 and non-type 2 inflammation in the airways. By neutralizing IL-33, QX007N aims to reduce airway inflammation and prevent exacerbations in patients with chronic obstructive pulmonary disease (COPD). As of late 2025, the drug is in the preclinical stage of development.

Targets

IL33 (IL-33)

Beyond the preview

Go deeper on QX007N.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QX007N.

Explore the full profile